NEW YORK (GenomeWeb News) - AstraZeneca has licensed Compendia Bioscience’s data mining and visualization software, Compendia said today.
AstraZeneca will use the company’s Oncomine Concepts Edition software in a year-long pilot program in order to evaluate how it can be used in its cancer research programs.
Oncomine combines almost 7,000 proprietary cancer gene signatures with 11,000 gene, drug, and pathway signatures taken from the literature and other public sources, Compendia said.
Financial terms of the agreement were not released.